Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label natalizumab tolerability in Crohn's disease (CD351 extension)
2004-003839-31Phase 3Completed
- Sponsor
- Elan
- Start
- May 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of natalizumab in Crohn's disease, sponsored by Elan. Primary endpoint: Long-term tolerability. Started May 2005; status: completed.
02
Drugs
natalizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2004-003839-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003839-31.